Ann: Race investor briefing & updated presentation, page-33

Hi Daniel @RaceOncology

This may be one of the sillier questions to come across your desk but it's not going to stop me asking it.

In regards to the FTO dose escalation trial, does this need to be done on people with the relevant cancers (or a single cancer type in particular, I'm not sure how the trial would run)?

Assuming we're talking about low doses, and Bisantrene has been shown to be safe (though not without side effects) at high doses, I was wondering if such a trial could be run on a range of people similar to those trials you hear about where uni students (for example) get paid a few thousand dollars to complete a trial?

For this to work would at a minimum would require that it's ethical to do so, that there is a relatively non-invasive way of measuring baseline FTO and FTO after treatment, and that FTO inhibition in 'regular' cells would be similar to what it would be in cancer cells. Probably some or none of these things are true, but I thought it was worth asking.

Thank you in advance.